Biological PharmaWeave

A revolutionary pharmaceutical medication developed by Cere as his first completed research project. It serves as a biological alternative to the Pharmaweave, designed specifically to help victims of severe skin injuries regain mobility.

Mechanism

The medication is delivered in pill form and works by instructing the body's own cells to grow a protective layer directly underneath the outermost skin layer. This bio-grown protection serves multiple functions:

Protection from further harm — shields damaged tissue from additional injury
Active treatment — continues treating wounded areas over time
Pressure capacity enhancement — significantly improves the skin's ability to withstand pressure without causing wound reopening
Mobility preservation — unlike Pharmaweave, does not impede flexibility or movement
Density control — can increase in density to redistribute applied pressure across the body, preventing simple activities like walking or stumbling from tearing open wounds

Development

Cere developed the medication in a "remarkably short time" after beginning his scientific research projects. The development was entirely digital, based on:

Extensive computer simulations
Scientific inference from current medical data
More up-to-date information than what Zet and Zeni had in their original knowledge bases

Critical limitation: The medication has never been physically tested. Cere pointed out that the process cannot be properly tested anywhere except on an actual human patient, as the interaction with human biology is too complex to fully simulate.

Dosage and Administration

Form: Pills
Frequency: One pill per week
Purpose: Replenish degraded protection as the layer naturally breaks down
Initial supply: 104 pills prepared (enough for two patients for one year)

Lifecycle

The protective layer has a one-week lifecycle:

Self-disassembles at the end of each week
Gets absorbed into the body naturally
Must be replenished with a new pill to maintain protection
Allows patients to discontinue treatment at any weekly interval

Intended Patients

Initially developed for two specific patients recovering at Telon:

Laylla Fynt — power transmission engineer injured in OPECS malfunction; candidate for restored walking ability
Vanessa Canly — recovering from radiation injuries; not yet recovered enough to benefit significantly

Risk Profile

Zeni Mason identified three worst-case scenarios for the medication (see IWUKE Chapter 39 for full risk analysis):

Density Control Failure — Under extreme circumstances, the layer could seize up at maximum density (plastic-sheet rigidity), causing pain, muscle strain, and potential material breakage leading to bleeding; lasts maximum one week before natural disassembly
System Rejection — Patient's immune system might attack the bio-grown layer, accelerating degradation (requiring more frequent dosing) and causing persistent fatigue; can be discontinued at any weekly checkpoint
Containment Failure — Modified cells could assimilate other cells and spread "cancerous"-like throughout the body, potentially causing organ damage; however, such mutations would be "easy to detect and trivial to remove"

All three scenarios are described as "very unlikely" hypotheticals based on extreme edge cases.

First Patient Trial (Chapter 41)

Decision:
Laylla Fynt decided to accept the treatment, messaging Zeni to begin the procedure. She had reviewed the risk analysis and deemed every point "acceptable" — noting that pain, bleeding, immobility, and even organ failure risk were things she already experienced.

Administration:
Zeni and Jake stayed with Laylla throughout the entire process:

Duration: Exactly 34 minutes from intake to completion
Patient experience: Described as "uncomfortable" — a sensation of a new organism spreading underneath the skin throughout the body
Laylla's response: Handled it without complaint, only occasional sighs and unfortunate facial expressions
Monitoring: Zeni used injected microbots to track vitals throughout

Immediate Results:
The moment the procedure completed:

Pain relief: Dramatically reduced — Laylla said "The pain is so much better. Even if this was all it was, and it wasn't going to let me walk, I'd be calling it a miracle"
Sitting up: Laylla sat up almost instantly and perfectly, with excellent posture
Emotional impact: "I could... You know, I could take care of myself"

First Steps:
With Jake's support initially, then independently:

Stood up with shaking legs but quickly stabilized
Took several steps completely on her own
Wide smile, tears running down her face
Zero pain while walking — first time in years

Vitals Check:
Monitoring showed:

"Incredible" results across all metrics
No hallmarks of any problems outlined in the risk analysis
Only notable reading: huge uptick in blood supply to leg muscles (expected, as they were doing unprecedented work)

First Real-World Test:
Less than an hour after treatment, Laylla walked nearly ten meters from her apartment to the community garden:

Used occasional fences and installations for support
Jake watched from the doorway
Her legs eventually failed, but Zeni caught her
Laylla was laughing: "There's no pain. This will help so many people."

Side Effects Observed:

Exhaustion: Muscles unused to the work required extensive recovery
Muscle weakness: Years of disuse meant even successful mobility required building strength
No adverse reactions: None of the three worst-case scenarios materialized

Follow-up:

Will require weekly reapplication (as designed)
Mertin Lagum may take over monitoring duties from Zeni, given his medical research background
Body must adjust to using muscles again even though tissue can now handle the strain

Current Status

As of Chapter 41, the treatment has proven successful in its first human trial:

✓ Laylla Fynt — treatment successful; can walk with minimal pain
Vanessa Canly — still not recovered enough to benefit significantly (awaiting future trial)

Significance

The successful first trial confirms this medication as a genuine breakthrough for severe skin trauma patients:

Restored mobility for a patient confined to bed for years
Eliminated chronic pain from tissue damage
No adverse reactions in first application
Potential to help countless others with similar injuries

Laylla's response — "This will help so many people" — suggests the technology could have planet-wide medical impact if production can be scaled.

The successful trial also resolves Zeni's ethical tension about untested technology: the treatment works, and the patient made an informed choice that proved correct.